Philips to acquire Spectranetics for $1.7B
- Highly complementary addition to Philips’ Image-Guided Therapy Business Group, strengthening its position in EUR 6+ billion market.
- Spectranetics’ strong device portfolio for vascular intervention and lead management procedures is growing double-digits.
- Spectranetics’ Stellarex [1] drug-coated balloon is a next-generation therapeutic device for the treatment of peripheral artery disease; Stellarex is backed by compelling clinical data, CE-marked, and under review by the FDA for premarket approval in the U.S.
- Philips is offering Spectranetics shareholders USD 38.50 in cash per share, which constitutes a 27 percent premium to Spectranetics closing price on June 27, 2017.
- Acquisition expected to be revenue growth, adjusted EBITA [2] margin and adjusted EPS [3] accretive for Philips by 2018.
Nov 06, 2024 by Nathan Gray, CRTonline.org
An ‘optimal’ procedural result of grade of 0/1+ regurgitation after tricuspid edge-to-edge repair (T-TEER) is associated with improved outcomes and functional status, according to an analysis of real-world patient data from the Spanish TRI-SPA registry.
Nov 06, 2024 by Will Chu, CRTonline.org
A new study outlines the substantial improvements in quality of life, symptom severity and exercise capacity among patients implanted with the Coronary Sinus (CS) Reducer in treating patients with refractory angina.
Nov 06, 2024 by Will Chu, CRTonline.org
Newly published findings reveal that the coronary sinus (CS) reducer significantly reduces angina symptoms and improves quality of life for patients with coronary microvascular dysfunction (CMD).